News Snapshot:
Week In Review: Qiming Closes $3.2 Billion For China Healthcare And Technology Investments Summary - Qiming Venture Partners closed two new China healthcare and technology funds with $3.2 billion in fresh capital, both of them at their hard cap limits. - Suzhou CStone Pharma announced that Gavreto® (pralsetinib) was approved in Hong Kong to treat adult patients with RET fusion-positive metastatic NSCLC. - Overland ADCT BioPharma, a JV created by Overland Pharma and Lausanne’s ADC Therapeutics, dosed the first patient in a China trial of Zynlonta® as a therapy for transfer-ineligible patients with diffuse large B-cell lymphoma (DLBCL). Deals and...
